|
DE19718012C1
(de)
*
|
1997-04-29 |
1998-10-08 |
Jenapharm Gmbh |
Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US6559158B1
(en)
*
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
NZ505192A
(en)
|
1997-12-22 |
2003-05-30 |
Euro Celtique S |
A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
|
|
US6277384B1
(en)
|
1997-12-22 |
2001-08-21 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
DE19853487A1
(de)
*
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
ES2540103T3
(es)
|
2000-02-08 |
2015-07-08 |
Euro-Celtique S.A. |
Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
|
|
WO2002092059A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
|
CA2446550C
(en)
|
2001-05-11 |
2012-03-06 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
|
DE60234183D1
(de)
|
2001-06-05 |
2009-12-10 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
|
DK1416842T3
(da)
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
|
PL367427A1
(en)
|
2001-08-06 |
2005-02-21 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
EP1436012B1
(en)
*
|
2001-10-18 |
2017-12-20 |
Nektar Therapeutics |
Polymer conjugates of opioid antagonists
|
|
KR100784341B1
(ko)
|
2002-04-05 |
2007-12-13 |
유로-셀띠끄 소시에떼 아노님 |
활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
|
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
|
RU2373936C2
(ru)
*
|
2003-04-08 |
2009-11-27 |
Проджиникс Фармасьютикалз, Инк. |
Применение метилналтрексона для лечения синдрома раздраженного кишечника
|
|
AU2013203378B2
(en)
*
|
2003-04-08 |
2016-09-15 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
CA2521420A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
|
HRP20150037T4
(hr)
*
|
2003-04-08 |
2022-09-02 |
Progenics Pharmaceuticals, Inc. |
Farmaceutske formulacije koje sadrže metilnaltrekson
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US20060182692A1
(en)
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
|
RS53279B
(sr)
*
|
2003-12-16 |
2014-08-29 |
Nektar Therapeutics |
Monodisperzne smeše pegilisanog naloksola
|
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
CA2595329A1
(en)
*
|
2005-01-20 |
2006-07-27 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
|
GEP20105052B
(en)
*
|
2005-01-28 |
2010-07-26 |
Euro Celtique Sa |
Alcohol resistant dosage forms
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
EP1695700A1
(en)
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
ES2714198T3
(es)
|
2005-03-07 |
2019-05-27 |
Univ Chicago |
Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
DE102006006532B4
(de)
|
2006-02-10 |
2007-11-08 |
Biogenerics Pharma Gmbh |
Pharmazeutische Zubereitung
|
|
ES2600141T3
(es)
|
2006-06-19 |
2017-02-07 |
Alpharma Pharmaceuticals Llc |
Composiciones farmacéuticas
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US20080139654A1
(en)
*
|
2006-12-09 |
2008-06-12 |
Eric Mott Soderling |
Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
|
|
SI2139890T1
(sl)
|
2007-03-29 |
2014-12-31 |
Wyeth Llc |
Antagonisti perifernih opioidnih receptorjev in njih uporaba
|
|
CL2008000905A1
(es)
|
2007-03-29 |
2008-08-22 |
Progenics Pharm Inc |
Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
|
|
CA2865389A1
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Crystal forms and uses thereof
|
|
US8748448B2
(en)
|
2007-10-18 |
2014-06-10 |
Aiko Biotechnology |
Combination analgesic employing opioid agonist and neutral antagonist
|
|
WO2009051824A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Aiko Biotechnology |
Combination analgesic employing opioid and neutral antagonist
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
WO2009099411A1
(en)
|
2008-02-06 |
2009-08-13 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
|
AU2009225434B2
(en)
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
|
JP5985824B2
(ja)
|
2008-07-01 |
2016-09-06 |
ザ ユニヴァーシティー オヴ シカゴ |
オピオイド受容体アンタゴニスト含有の粒子および使用方法
|
|
CA2676881C
(en)
*
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
SMT201900023T1
(it)
|
2009-03-10 |
2019-02-28 |
Euro Celtique Sa |
Composizioni farmaceutiche a rilascio immediato comprendenti ossicodone e naloxone
|
|
WO2010151741A1
(en)
*
|
2009-06-25 |
2010-12-29 |
Elite Laboratories, Inc. |
Abuse resistant oral dosage forms
|
|
SG10201501821RA
(en)
|
2010-03-11 |
2015-05-28 |
Wyeth Llc |
Oral formulations and lipophilic salts of methylnaltrexone
|
|
JP5840201B2
(ja)
|
2010-05-10 |
2016-01-06 |
ユーロ−セルティーク エス．エイ． |
活性剤を負荷した顆粒と追加の活性剤の組合せ
|
|
KR20130030260A
(ko)
|
2010-05-10 |
2013-03-26 |
유로-셀티큐 에스.에이. |
히드로모르폰 및 날록손을 포함하는 제약 조성물
|
|
NZ603173A
(en)
|
2010-05-10 |
2014-10-31 |
Euro Celtique Sa |
Manufacturing of active-free granules and tablets comprising the same
|
|
WO2015011189A1
(en)
|
2013-07-23 |
2015-01-29 |
Euro-Celtique S.A. |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
JP6539274B2
(ja)
|
2013-08-12 |
2019-07-03 |
ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド |
押出成形された即放性乱用抑止性丸剤
|
|
DE112014005175T5
(de)
|
2013-11-13 |
2016-07-21 |
Euro-Celtique S.A. |
Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom
|
|
US10105360B2
(en)
|
2013-12-11 |
2018-10-23 |
Develco Pharma Schweiz Ag |
Method and composition for the treatment of opioid induced constipation
|
|
US9456986B2
(en)
|
2013-12-11 |
2016-10-04 |
Develco Pharma Schweiz Ag |
Naloxone mono preparation and multilayer tablet
|
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
EP3169315B1
(en)
|
2014-07-17 |
2020-06-24 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
CA3002137A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
|
US20160106737A1
(en)
|
2014-10-20 |
2016-04-21 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended Release Abuse Deterrent Liquid Fill Dosage Form
|
|
US20160256451A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Dosage of naloxone
|
|
US20160256452A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
WO2016193456A2
(en)
|
2015-06-03 |
2016-12-08 |
Develco Pharma Schweiz Ag |
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3290027A1
(en)
|
2016-09-02 |
2018-03-07 |
Develco Pharma Schweiz AG |
Method and composition for the treatment of opioid induced constipation
|
|
CN113747882A
(zh)
|
2019-05-07 |
2021-12-03 |
博士医疗爱尔兰有限公司 |
甲基纳曲酮的液体口服剂量制剂
|